Cover Image




ABSTRACT BACKGROUND MDR TB is an              emerging threat all over the world. Planning the programmatic management of MDR TB necessitates the need for many            studies regarding the prevalence and demographic pattern in various regions. METHODS This was a cross sectional study done in a tertiary care centre in which the diagnosis of MDR TB is done by CBNAAT (GENE XPERT). The sputum samples were sent to a higher centre for analysis. The data from a            register in the Dept. Of Thoracic medicine were collected and analysed. RESULTS The prevalence of MDR TB was 18.56 among MDR TB suspected cases. The inference of the study was that the prevalence was more among previously treated cases, male patients, more than 30 yrs of age and among rural population. This pattern may differ in other regions.                   CONCLUSION MDR TB being an increasing global problem needs more surveillance and monitoring which will help in the proper planning of the diagnostic approach and therapeutic interventions. More studies are needed to accomplish this in various regions.


Full Text:



(1) British medical bulletin 2005; 73 and 74: Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment L. P. Ormerod 17–24 DOI: 10.1093/bmb/ldh047

(2) WHO: global tuberculosis report 2012;WHO/HTM/TB/2012.6

(3) Suarez PG, Floyd K, Porto carrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359:1980–9.

(4)Van Rie, A., Page-Shipp, L., Scott, L., Sanne, I., Stevens, W. (2010) "Xpert® MTB/RIF for point-ofcare diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?" Expert Rev. Mol. Diagn. 10: 937-946

(5) Helb, D., et al (2010) "Rapid detection of Mycobacterium tuberculosis and Rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 48: 229-237

(6) Boehme, C. C., et al. (2010) "Rapid molecular detection of tuberculosis and rifampin resistance" N. Engl. J. Med. 363: 1005-1015

(7) Drobniewski FA, Pozniak AL. (1996) Molecular diagnosis, detection of drug resistance and epidemiology of tuberculosis. Br J Hosp Med, 56, 204–8.

(8) Revised National TuberculosisControl Programme: Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India. May 2012 Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare, Nirman Bhavan, New Delhi – 110011

(9)Risk factors for multidrug resistant tuberculosis in Europe: a systematic review, thorax 2006 61: 158-163. Doi: 10.1136/thx.2005.045963

(10) Multi-drug resistant TB prevalence three times high in north India: Study: BMC Infectious Diseases 2013, 13:137 doi: 10.1186 /1471-2334-13-137. Sunil Sethi, microbiology department, and Dheeraj Gupta, pulmonary medicine.

(11) Incidence of Multidrug-Resistant Tuberculosis in Urban and Rural India and Implications for Prevention. Deepak Almeida,1 Camilla Rodrigues,2 Zarir F. Udwadia,3 Ajit Lalvani,6G. D. Gothi,4 Pravin Mehta,5 and Ajita Mehta2 Clinical Infectious Diseases 2003; 36:e152–4

(12) Determinants of drug resistant tuberculosis: analysis of 11 countries. M.A.Espinal, K.Laserson, International J Tuberculosis Lung Diseases 5(10): 887-893: IUATLD.

(13) Is HIV infection a risk factor for multidrug resistant tuberculosis? A systematic review. Sujit Suchindran, Emily S.Browser, Annelies Van Rie Plos ONE 4(5): e 5561.doi: 10.1371/journal.pone.0005561.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr M.G.R. Medical University